We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 1 of 1 for:    RMC-6291
Previous Study | Return to List | Next Study

Dose Escalation and Dose Expansion Study of RMC-6291 Monotherapy in Subjects With Advanced KRASG12C Mutant Solid Tumors

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT05462717
Recruitment Status : Recruiting
First Posted : July 18, 2022
Last Update Posted : September 22, 2022
Sponsor:
Information provided by (Responsible Party):
Revolution Medicines, Inc.

Brief Summary:
The purpose of this study is to evaluate the safety, tolerability, and pharmacokinetics (PK) of escalating doses of RMC-6291 (KRAS G12C(ON) inhibitor) monotherapy in adult subjects with advanced solid tumors and to identify the maximum tolerated dose (MTD), and the recommended Phase 2 dose.

Condition or disease Intervention/treatment Phase
Non-Small Cell Lung Cancer (NSCLC) Colorectal Cancer (CRC) Pancreatic Ductal Adenocarcinoma Advanced Solid Tumor Drug: RMC-6291 Phase 1

Detailed Description:
This is an open-label, multicenter, Phase 1/1b study of RMC-6291 monotherapy in subjects with advanced KRASG12C-mutant solid tumors. The study will include 2 components: a Dose-Escalation and a Dose-Expansion. Subjects will be treated until disease progression per RECIST v1.1, unacceptable toxicity, or other criteria for withdrawal are met, whichever occurs first.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 117 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Phase 1/1b, Multicenter, Open-Label, Dose Escalation and Dose Expansion Study of RMC-6291 Monotherapy in Subjects With Advanced KRASG12C Mutant Solid Tumors
Actual Study Start Date : September 19, 2022
Estimated Primary Completion Date : November 2024
Estimated Study Completion Date : December 2025


Arm Intervention/treatment
Experimental: RMC-6291
Dose Escalation and Dose Expansion
Drug: RMC-6291
Oral tablet once or twice a day




Primary Outcome Measures :
  1. Adverse events [ Time Frame: up to 3 years ]
    Number of participants with adverse events

  2. Dose Limiting Toxicities [ Time Frame: The first 21 days (i.e. Cycle 1) ]
    Number of participants with dose limiting toxicities


Secondary Outcome Measures :
  1. Maximum Observed Blood Concentration of RMC-6291 [ Time Frame: 7 Cycles ]
    Cmax

  2. Time to Reach Maximum Blood Concentration of RMC-6291 [ Time Frame: 7 Cycles ]
    Tmax

  3. Area Under Blood Concentration Time Curve of RMC-6291 [ Time Frame: 7 Cycles ]
    AUC

  4. Elimination Half-Life of RMC-6291 [ Time Frame: 7 Cycles ]
    t1/2

  5. Ratio of accumulation of RMC-6291 from a single dose to steady state with repeated dosing [ Time Frame: 7 Cycles ]
    accumulation ratio

  6. Overall Response Rate (ORR) [ Time Frame: 3 years ]
    Overall response rate per RECIST v1.1

  7. Duration of Response (DOR) [ Time Frame: 3 years ]
    Duration of response per RECIST v1.1

  8. Disease Control Rate (DCR) [ Time Frame: 3 years ]
    Disease control rate per RECIST v1.1

  9. Time to Response (TTR) [ Time Frame: 3 years ]
    Time to response per RECIST v1.1

  10. Progression-Free Survival (PFS) [ Time Frame: 3 years ]
    Progression-free survival per RECIST v1.1



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Subject must be ≥18 years of age.
  • Subject must have pathologically documented, locally advanced or metastatic KRASG12C-mutated solid tumor malignancy (not amenable to curative surgery) that has previously been treated with standard-of-care therapies for respective tumor types, is intolerant to, or is considered ineligible for standard-of-care anticancer treatments.
  • ECOG performance status 0 or 1
  • Prior treatment with a KRASG12C (OFF) inhibitor allowed for dose escalation
  • Adequate organ function

Exclusion Criteria:

  • Primary central nervous system (CNS) tumors
  • Active brain metastases
  • Known impairment of GI function that would alter the absorption
  • Major surgical procedures within 28 days or non-study-related minor procedures within 7 days of treatment.
  • Prior therapy with KRASG12C (ON) inhibitor

Other inclusion/exclusion criteria may apply.


Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT05462717


Contacts
Layout table for location contacts
Contact: Revolution Medicines, Inc. (650) 779-2300 CT-inquiries@RevMed.com

Locations
Layout table for location information
United States, Arkansas
Highlands Oncology Group Recruiting
Springdale, Arkansas, United States, 72762
United States, Maryland
American Oncology Partners of Maryland Recruiting
Bethesda, Maryland, United States, 20817
United States, Tennessee
Tennessee Oncology Recruiting
Nashville, Tennessee, United States, 37203
United States, Texas
Next Oncology Recruiting
San Antonio, Texas, United States, 78229
START Recruiting
San Antonio, Texas, United States, 78229
United States, Virginia
Next Oncology Virginia Recruiting
Fairfax, Virginia, United States, 22031
Sponsors and Collaborators
Revolution Medicines, Inc.
Investigators
Layout table for investigator information
Study Director: Revolution Medicines, Inc. Revolution Medicines, Inc.
Layout table for additonal information
Responsible Party: Revolution Medicines, Inc.
ClinicalTrials.gov Identifier: NCT05462717    
Other Study ID Numbers: RMC-6291-001
First Posted: July 18, 2022    Key Record Dates
Last Update Posted: September 22, 2022
Last Verified: September 2022
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Revolution Medicines, Inc.:
RMC-6291
RAS(ON)
KRAS
KRASG12C
KRASG12C(ON)
Targeted therapy
Metastatic cancer
Lung Cancer
Lung Neoplasms
Thoracic Neoplasms
Non-small Cell Lung Cancer
Carcinoma, Non-Small Cell Lung
NSCLC
Colorectal Cancer
Colonic Neoplasms
CRC
Appendiceal Cancer
KRAS mutation
STK11/LKB1
KEAP1
bronchial neoplasms
respiratory tract neoplasms
neoplasms by site
neoplasms
Colon Cancer
Rectal Cancer
lung disease
respiratory tract diseases
Pancreatic Cancer
Carcinoma, Pancreatic Ductal
Additional relevant MeSH terms:
Layout table for MeSH terms
Lung Neoplasms
Carcinoma, Non-Small-Cell Lung
Colorectal Neoplasms
Respiratory Tract Neoplasms
Thoracic Neoplasms
Neoplasms by Site
Neoplasms
Lung Diseases
Respiratory Tract Diseases
Carcinoma, Bronchogenic
Bronchial Neoplasms
Intestinal Neoplasms
Gastrointestinal Neoplasms
Digestive System Neoplasms
Digestive System Diseases
Gastrointestinal Diseases
Colonic Diseases
Intestinal Diseases
Rectal Diseases